The drug fosdenopterin/rcPMP considerably improves the chances of survival and developmental progress in infants with ...

Editas Medicine struggles with underwhelming data and lacks major partnerships. Find out why EDIT stock faces significant ...

The Company recently confirmed that the preliminary HLA prevalence, safety, and immune response data in FLAMINGO-01 patients is trending as expected in both HLA-A*02 and non-HLA-A*02 arms. The non-HLA ...

Q4 2024 Earnings Call Transcript March 31, 2025 Brainstorm Cell Therapeutics Inc. reports earnings inline with expectations.

Marks’ resignation leaves the field without a regulator many view as “integral” to its progress over the last decade.